WAVEMAN · COMPANY

TSSI · Tss, Inc.

LIVE

TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475

← ALL COMPANIES

TSSI

Name: TSS, Inc. (TSSI) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

TSS, Inc.

PHARMA & BIOTECH · SERVICES-MANAGEMENT CONSULTING SERVICES · CIK 0001320760

C-SUITE BUYING · 1☆ WATCH

INSIDER NET · 180D

-$8.4M

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

+65.9%

XBRL, annual

NET MARGIN

6.2%

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$8.4M over 180 days

below 83% of Pharma & Biotech

CONGRESS

no member of Congress has reported trading it

FUNDS

91 funds added or opened last quarter

more than 62% of Pharma & Biotech

REVENUE

+65.9% year over year

more than 82% of Pharma & Biotech

MARGIN

6.2% net margin

more than 75% of Pharma & Biotech

BUYBACKS

$2.2M repurchased, FY to 2026-06-30

below 83% of Pharma & Biotech

SHORT

no short interest reported

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

Insiders are net sellers: -$8.4M across 5 people in 180 days.

91 funds added or opened positions in the latest 13F quarter, of 126 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN -40.0%

-40.0%12M

INSIDER BUYINSIDER SELL

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

The complete filing record, in one place.

The record shows a net $8.4M sold by insiders over 180 days, 91 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, TSS, Inc. insiders sold a net $8.4M of stock across 57 Form 4 purchases and sales, with 1 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-04.

INSIDER

FILED

VALUE

Woodward Peter H

Director

SELL

2026-06-02

100,000.0

$1.5M

Brennan Kieran

Senior Vice President

SELL

2026-06-01

10,000.0

$160.0K

Woodward Peter H

Director

SELL

2026-05-29

200,000.0

$3.2M

HEATON LARRY C II

CEO

BUY

2026-05-08

250,000.0

$27.5K

Dewan Darryll E

Chief Executive Officer

SELL

2026-05-06

50,000.0

$850.0K

57 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 52 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

BlackRock, Inc.

2,322,290.0 sh

$28.6M

JANE STREET GROUP, LLC

1,047,184.0 sh

$12.9M

VANGUARD CAPITAL MANAGEMENT LLC

966,509.0 sh

$11.9M

SILVERCREST ASSET MANAGEMENT GROUP LLC

681,700.0 sh

$8.4M

GEODE CAPITAL MANAGEMENT, LLC

626,884.0 sh

$7.7M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Hedgeye 130/30 Equity ETF

$358.1K POSITION · AS OF 2026-04-30

1.4%

iShares Micro-Cap ETF

$719.9K POSITION · AS OF 2026-03-31

0.1%

AVIP BlackRock Advantage Small Cap Growth Portfolio

$71.3K POSITION · AS OF 2026-03-31

0.1%

TEXAS CAPITAL TEXAS EQUITY INDEX ETF

$18.1K POSITION · AS OF 2026-03-31

0.1%

Goldman Sachs Small Cap Equity Insights Fund

$324.0K POSITION · AS OF 2026-04-30

0.0%

Goldman Sachs Small Cap Growth Insights Fund

$124.2K POSITION · AS OF 2026-04-30

0.0%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$245.7M	$148.1M	$54.4M	$30.6M
GROSS PROFIT	$32.4M	$22.4M	$11.0M	$9.0M
OPERATING INCOME	$6.3M	$5.8M	$-221.0K	$914.0K
NET INCOME	$15.1M	$6.0M	$74.0K	$-73.0K
EPS (DILUTED)	0.56	0.24	0.00	0.00
OPERATING CASH FLOW	$34.9M	$15.3M	$-8.3M	$14.7M
CASH	$85.5M	$23.2M	$11.8M	$20.4M
LONG-TERM DEBT	$14.0M	$8.2M	$0	$0
BUYBACKS	$4.9M	$4.5M	$40.0K	$134.0K

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-04 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE